Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation  Sung-Doo.

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors Ji-Man Kang, Yae-Jean Kim,
CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning  Jamie H. Zao, Tal Schechter, Wenchao Jessica.
Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.
Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.
Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.
How to Treat MDS without Stem Cell Transplantation
Unrelated Donor Bone Marrow Transplants for Severe Aplastic Anemia with Conditioning Using Total Body Irradiation and Cyclophosphamide  Sung-Yong Kim,
IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies  L. Lee Dupuis, Cathryn Sibbald,
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Clinical Characteristics and Prognostic Factors of Primary Pulmonary Vein Stenosis or Atresia in Children  Mi Kyoung Song, MD, Eun Jung Bae, MD, Soo In.
Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease  Meerim Park, Soo.
Increased Copy Number of the Interleukin-6 Receptor Gene Is Associated with Adverse Survival in Multiple Myeloma Patients Treated with Autologous Stem.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 
CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease  Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.
Sabina Kersting, Leo F. Verdonck 
Access to Hematopoietic Cell Transplantation in the United States
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children: Analysis of Prognostic Factors  Ji-Man Kang, Yae-Jean Kim,
A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous.
Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome  Sung-Soo Park, Young-Woo.
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical.
Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning  Jamie H. Zao, Tal Schechter, Wenchao Jessica.
High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Stratification of de novo Adult Acute Myelogenous Leukemia with Adverse-Risk Karyotype: Can We Overcome the Worse Prognosis of Adverse-Risk Group Acute.
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation  Seong-Gil.
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy.
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Excellent Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Acquired Severe Aplastic Anemia  Ho Joon.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Polymorphisms in Genes That Regulate Cyclosporine Metabolism Affect Cyclosporine Blood Levels and Clinical Outcomes in Patients Who Receive Allogeneic.
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma 
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pauline Damien, David S. Allan 
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Participation in Clinical Research: Perspectives of Adult Patients and Parents of Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation 
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives  Minakshi Raj, Sung Won Choi,
Blood and Marrow Transplant Handbook
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Successful Engraftment with Fludarabine, Cyclophosphamide, and Thymoglobulin Conditioning Regimen in Unrelated Transplantation for Severe Aplastic Anemia:
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia  SungNam Lim, Je-Hwan Lee, MD, PhD,
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Luciano J. Costa, Jia-Xing Huang, Parameswaran.
Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory.
Graft-versus-Tumor Effect According to Type of Graft-versus-Host Disease Defined by National Institutes of Health Consensus Criteria and Associated Outcomes 
Presentation transcript:

Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation  Sung-Doo Kim, Je-Hwan Lee, Eun-Hye Hur, Jung-Hee Lee, Dae-Young Kim, Sung-Nam Lim, Yunsuk Choi, Hyeong-Seok Lim, Kyun- Seop Bae, Gyu-Jeong Noh, Sung-Cheol Yun, Sang Beom Han, Kyoo-Hyung Lee  Biology of Blood and Marrow Transplantation  Volume 17, Issue 8, Pages 1222-1230 (August 2011) DOI: 10.1016/j.bbmt.2010.12.708 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Comparison of busulfan clearance distribution according to GST genotypes. Horizontal lines indicate the means of each group. (A) GSTA1, (B) GSTM1, (C) GSTT1, and (D) GSTM1/GSTT1-null genotype (ie, the number of GSTM1- and GSTT1-null genotypes). Biology of Blood and Marrow Transplantation 2011 17, 1222-1230DOI: (10.1016/j.bbmt.2010.12.708) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Clearance of i.v. busulfan according to GST gene polymorphism. Horizontal lines indicate the means of each group. Busulfan clearance was grouped by GSTA1 genotype and GSTM1/GSTT1-null genotype (ie, the number of GSTM1- and GSTT1-null genotypes). Biology of Blood and Marrow Transplantation 2011 17, 1222-1230DOI: (10.1016/j.bbmt.2010.12.708) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.